Sartorius Stedim Biotech Past Earnings Performance
Past criteria checks 1/6
Sartorius Stedim Biotech has been growing earnings at an average annual rate of 17%, while the Life Sciences industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 18.5% per year. Sartorius Stedim Biotech's return on equity is 6.7%, and it has net margins of 9.4%.
Key information
17.0%
Earnings growth rate
16.9%
EPS growth rate
Life Sciences Industry Growth | 36.9% |
Revenue growth rate | 18.5% |
Return on equity | 6.7% |
Net Margin | 9.4% |
Next Earnings Update | 19 Jul 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Sartorius Stedim Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 2,716 | 255 | 625 | 129 |
31 Dec 23 | 2,776 | 310 | 618 | 130 |
30 Sep 23 | 2,959 | 460 | 598 | 131 |
30 Jun 23 | 3,170 | 635 | 603 | 132 |
31 Mar 23 | 3,356 | 717 | 604 | 135 |
31 Dec 22 | 3,493 | 876 | 612 | 132 |
30 Sep 22 | 3,381 | 681 | 605 | 125 |
30 Jun 22 | 3,259 | 625 | 577 | 123 |
31 Mar 22 | 3,094 | 559 | 564 | 119 |
31 Dec 21 | 2,887 | 414 | 532 | 111 |
30 Sep 21 | 2,639 | 523 | 479 | 103 |
30 Jun 21 | 2,393 | 469 | 450 | 98 |
31 Mar 21 | 2,143 | 398 | 417 | 89 |
31 Dec 20 | 1,910 | 336 | 392 | 84 |
30 Sep 20 | 1,743 | 299 | 373 | 84 |
30 Jun 20 | 1,600 | 255 | 353 | 81 |
31 Mar 20 | 1,520 | 254 | 334 | 81 |
31 Dec 19 | 1,441 | 235 | 318 | 79 |
30 Sep 19 | 1,393 | 247 | 308 | 68 |
30 Jun 19 | 1,336 | 238 | 301 | 65 |
31 Mar 19 | 1,274 | 223 | 293 | 61 |
31 Dec 18 | 1,212 | 208 | 283 | 61 |
30 Sep 18 | 1,172 | 185 | 277 | 60 |
30 Jun 18 | 1,121 | 173 | 264 | 59 |
31 Mar 18 | 1,093 | 162 | 259 | 57 |
31 Dec 17 | 1,081 | 161 | 258 | 53 |
30 Sep 17 | 1,073 | 151 | 252 | 53 |
30 Jun 17 | 1,089 | 157 | 255 | 50 |
31 Mar 17 | 1,075 | 157 | 250 | 49 |
31 Dec 16 | 1,052 | 154 | 244 | 48 |
30 Sep 16 | 1,009 | 145 | 242 | 47 |
30 Jun 16 | 971 | 142 | 234 | 46 |
31 Mar 16 | 926 | 136 | 226 | 43 |
31 Dec 15 | 884 | 118 | 217 | 42 |
30 Sep 15 | 850 | 111 | 207 | 43 |
30 Jun 15 | 781 | 89 | 197 | 35 |
31 Mar 15 | 734 | 76 | 189 | 39 |
31 Dec 14 | 684 | 72 | 184 | 34 |
30 Sep 14 | 646 | 71 | 173 | 39 |
30 Jun 14 | 620 | 67 | 168 | 39 |
31 Mar 14 | 604 | 68 | 165 | 38 |
31 Dec 13 | 588 | 66 | 159 | 36 |
30 Sep 13 | 567 | 63 | 151 | 34 |
30 Jun 13 | 564 | 65 | 155 | 33 |
Quality Earnings: 0RG8 has a large one-off gain of €59.6M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 0RG8's current net profit margins (9.4%) are lower than last year (21.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0RG8's earnings have grown by 17% per year over the past 5 years.
Accelerating Growth: 0RG8's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 0RG8 had negative earnings growth (-64.5%) over the past year, making it difficult to compare to the Life Sciences industry average (6.5%).
Return on Equity
High ROE: 0RG8's Return on Equity (6.7%) is considered low.